SAA1 and atherosclerosis: The primary aim of this study is to investigate whether SAA-mediated renal and vascular dysfunction can be ameliorated with 4-metT administered either before (prophylaxis) or after (therapeutic) supplementing recombinant SAA in atherosclerosis-prone apolipoprotein E-deficient (ApoE−/−) mice.